tiprankstipranks
Advertisement
Advertisement

ANVS Stock Latest News

Annovis Bio promotes Cheng Fang to chief scientific officer
The FlyAnnovis Bio promotes Cheng Fang to chief scientific officer
4d ago
ANVS
Annovis Bio Shareholders Approve Governance and Compensation Changes
PremiumCompany Announcements
Annovis Bio Shareholders Approve Governance and Compensation Changes
18d ago
8K
ANVS
Annovis Bio: Buy Rating Reiterated as Late-Stage Neurodegenerative Pipeline Advances; $8 Price Target Unchanged
PremiumRatings
Annovis Bio: Buy Rating Reiterated as Late-Stage Neurodegenerative Pipeline Advances; $8 Price Target Unchanged
1M ago
ANVS
Annovis Bio regains NYSE listing compliance
PremiumThe Fly
Annovis Bio regains NYSE listing compliance
1M ago
ANVS
Annovis Bio Announces Dilutive Equity Offering for Trials
PremiumCompany Announcements
Annovis Bio Announces Dilutive Equity Offering for Trials
2M ago
8K
ANVS
Annovis Bio 7.9M share Spot Secondary priced at $1.90
PremiumThe FlyAnnovis Bio 7.9M share Spot Secondary priced at $1.90
2M ago
ANVS
Closing Bell Movers: Roblox up 4% on buyback, Keysight gains on earnings
Premium
The Fly
Closing Bell Movers: Roblox up 4% on buyback, Keysight gains on earnings
2M ago
DRS
JHX
Annovis Bio announces common stock and warrants offering, no amount given
Premium
The Fly
Annovis Bio announces common stock and warrants offering, no amount given
2M ago
ANVS
Annovis Bio Prices Registered Direct Offering to Fund Trials
PremiumCompany Announcements
Annovis Bio Prices Registered Direct Offering to Fund Trials
3M ago
8K
ANVS
Annovis Bio secures U.S. patent for buntanetap
PremiumThe Fly
Annovis Bio secures U.S. patent for buntanetap
3M ago
ANVS
Annovis Bio enters partnership with NeuroRPM
PremiumThe Fly
Annovis Bio enters partnership with NeuroRPM
4M ago
ANVS
Annovis Bio sees cash runway to 3Q26
PremiumThe Fly
Annovis Bio sees cash runway to 3Q26
4M ago
ANVS
Annovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
PremiumThe FlyAnnovis Bio reports FY25 EPS ($1.40) vs. ($2.31) last year
4M ago
ANVS
Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
Premium
Ratings
Annovis Bio: Advancing Phase 3 Neurodegeneration Programs Create Attractive Risk‑Reward Supporting Buy Rating
4M ago
ANVS
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
Premium
Company Announcements
Annovis Bio Advances Alzheimer’s Phase 3 Trial After Safety Nod
5M ago
8K
ANVS
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
PremiumThe Fly
Annovis Bio secures DSMB approval to advance Phase 3 trial of buntanetap
5M ago
ANVS
Annovis Bio Hosts Regulation FD Investor Information Webinar
PremiumCompany Announcements
Annovis Bio Hosts Regulation FD Investor Information Webinar
5M ago
8K
ANVS
Annovis Bio reports open-label extension study for Parkinson’s disease patients
PremiumThe Fly
Annovis Bio reports open-label extension study for Parkinson’s disease patients
7M ago
ANVS
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
PremiumCompany Announcements
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
7M ago
ANVS
Annovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap
PremiumRatingsAnnovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap
8M ago
ANVS
Annovis announces FDA meeting to discuss PDD program
Premium
The Fly
Annovis announces FDA meeting to discuss PDD program
8M ago
ANVS
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
Premium
The Fly
Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
8M ago
ANVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >